UBS AG buy 8,825,000 6.7%

eSensor LAUNCHED!!!

FDA clearance for Cystic Fibrosis DNA Test

Sales of the eSensor instrument and CF test will commence in the first half of 2006 as planned.. . James White, CEO of Osmetech said: 'Gaining FDA clearance for our first microarray based test developed for our new eSensorTM molecular diagnostics instrument is a major step forward for our Molecular Diagnostics Division and will help to establish Osmetech as a key player in the fast growing moleculardiagnostics market. In addition, this FDA clearance helps to validate our microarray technology for routine use in the laboratory. Critical Care DivisionThe Division has a strong product portfolio and is well placed to continue the growth of instrument placements throughout the world, leading to revenues from proprietary consumables for a number of years to come.Sales of OPTI instruments and consumables remained strong resulting from increased sales of the new touchscreen version of the long-established OPTI (CCA). In 2006 we will start to see an important contribution to sales from the new OPTI LION portable electrolyte analyser and the OPTI R blood gas and electrolyte analyser with reusable consumable as these products are rolled out internationally.' Molecular Diagnostics DivisionFollowing FDA approval of the eSensorTM platform Osmetech are now looking to progress discussions with strategic partners who are looking for cost effective and easy to use instrumentation and consumables to work on other complex assays both in the healthcare and non healthcare markets. The next Osmetech Molecular test targeted for FDA submission will be the CYP 450 pharmacogenomics assay, which is currently in development. James White, CEO of Osmetech commented: 'We have been delighted with the rapid integration of the CMS business acquired in July. The powerful combination of the eSensor product together with OPTI GENE provides Osmetech Molecular Diagnostics with an excellent position in this rapidly developing and growing market sector. Both products remain on schedule for launch and revenue generation in the first half of 2006'

Sales to year end up over 40%

Osmetech has reported a strong rise in sales in the latter part of 2005 with growth driven byabove-forecast revenues at its Critical Care blood gas analysis division.. Sales for the Critical Care division in calendar year 2005 exceeded $14.7m, representing an increase of over 60% compared to the calendar year 2004. Approximately half of this overall growth is due to sales to veterinary distribution partner, IDEXX Laboratories, Inc.

Vetstat Exceeds Idexx Expectations

Sales of the VetStat electrolyte and blood gas analyser have been very encouraging and continue to exceed expectations. IDEXX's sales successes and continuing marketing efforts should result in further strong growth for the foreseeable future. As the installed base of instruments becomes established, revenues from proprietary consumables are expected to increase as a proportion of this veterinary business. Following a deal with leading US vetinary hopsital chain Banfield, Idexx are contracted to supply an additional 450 Vetstat devices over the coming year.Good progress is also being made with IDEXX on the development and supply contract to create a new platform for measuring critical care parameters based on Osmetech's proprietary optical fluorescence technology and consumables. It is anticipated that this market leading product is on target for launch late 2006/2007.

Critical Care Product Range - In Production

OPTI-CCA OPTI-LION OPTI-R OPTI-2L

Critical Care Consumable Product Range - In Production

SamplerCassette Callibration DataTrol

Molecular Diagnostics Product Range - In Production

Opti-GeneeSensorBiochipConsumableOPTI Tube Product Range - Licenced to Third Party

VetStat Cassettes OPTI Tube AVOX 4000

Buisness Partners

Major Shareholders

Organisation Shareholding % Gartmore 24,109,657 18.29% Schroder 18,874,284 14.32 UBS AG 8,825,000 6.70TD Waterhouse 7,011,137 5.32 Barclays Nom 6,638,092 5.04 Pershing Keen 5,870,773 4.45HSBC Global Nom 6,544,718 4.97 Roche 2,444,688 1.8 Marlborough UK Micro Cap Director Holdings James White 208,092 Gordon Hall 104,966 D Sandilands 61,597 GB Kuenster 33,054 A Marek 26,190 ADVFN Posters 5,896,564 4.5 Total Holdings 86,648,812 65.7%

Mouse Over Images For Product Data

If regular posters would like to be included in the ADVFN figure and if you are not bothered about the figures being public then post your long-term holding here.IE the number of shares you intend to keep for say more than 6 months?Alternatively if you'd rather keep your holdings secret but still want contribute to the overall figure then drop me a line to ditchpig@ntlworld.com

Of course.

Monkey shake the tree, all the coconouts fall out.

Hold tight!

Big Al says:-

OMH - agreement opens verterinarian market to technology. "The impact upon the next financial year should be significant".
Might fly!!
http://moneyam.uk-wire.com/cgi-bin/articles/200408060700086991B.html
Results - http://moneyam.uk-wire.com/cgi-bin/articles/200408060700086992B.html

Ha......who's gonna blink first. Time to enter m'thinks.
regards

Massive buys already 5M and rising.

Not at all surprised here with the news and results.

could we reach 10m buys today :-))

The vet tie-up came as a bit of a surprise, another market to tap in to and quite a big one by the looks of it, 10 million looks easy today, I wonder how long the price will be kept down? As long as it stays this low, it surely must be regarded as a buying opportunity?

Good luck to all

Regards

PTH

still keeping the price down, surprised by this after .45p gain just before the start of trading, buying seems to have slowed down as day goes on, results and positive news all good but price is not reflecting this as yet hope to see it rise soon :-))

What time frame are we looking at on this one +12 months or longer.

Christ. What does this company have to do to get a positive reaction from the share price? Some truely fantastic news buys 3 million more than the number of sells and we end up down. EVO have killed any rise today by sitting on the offer all day. I wonder what their game is.
I'll update the header with the new info over the weekend.

still going down shocked to see such a down turn in the price was expecting it to rise this week anyone with views to why the price is still going down, with the company giving us the best news we have had for a long time and getting closer to making a profit next year this is only good for the price surely :-((

Morning All, Does Anyone Know the date of the final results yet, (due Q3 2004 )

some people amaze me.....LoL

why are they keeping the price down what are they affraid of, this comapny is doing well with plenty in the pipe line but still they fall ;-( is there any ryhme or reason for this surley they should be 6p by now...

Hmmm....Maybe the MM's are too surley. Miserable bastardo's :-)
regards

So whats happening to the share price. Maybe the city just dont like them?cant sit on this much longer. Good news and a declining share price do not send the right messages

More good news from OMH.

Osmetech PLC
01 September 2004


1 September 2004




NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO
THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION



Recommended Offer by Evolution Beeson Gregory on behalf of Osmetech plc to
acquire the whole of the issued and to be issued share capital of Molecular
Sensing plc


Summary




Recommended share for share offer, that will be made by Evolution
Beeson Gregory on behalf of Osmetech, for the entire issued and to be issued
share capital of Molecular Sensing on the basis of 47 new Osmetech Shares for
every two Molecular Sensing Shares.



Offer values the existing ordinary share capital of Molecular Sensing
at approximately 3.1 million and each Molecular Sensing Share at approximately
86.4 pence, on the basis of the Closing Price of 3.675p per Osmetech Share on 31
August 2004 (the last dealing day prior to the publication of this
announcement).



Offer price represents a premium of approximately 92 per cent. to the
Molecular Sensing Closing Price of 45 pence per Molecular Sensing Share at the
close of business on 31 August 2004 (the last dealing day prior to the
publication of this announcement).



The Independent Molecular Sensing Directors, who have been so advised by
Insinger de Beaufort, consider that the terms of the Offer are fair and
reasonable and the Independent Molecular Sensing Directors will recommend all
Molecular Sensing Shareholders to accept the Offer. In providing advice to the
Independent Molecular Sensing Directors, Insinger de Beaufort has taken into
account the commercial assessments of the Independent Molecular Sensing
Directors.



Commenting on the Offer, James White, Chief Executive of Osmetech said:



'We have evaluated a variety of alternatives to achieve our strategic aim of
expanding the non-OPTI revenue base, utilising our existing distribution network
more effectively and enhancing the attractiveness of our vaginal infection
product ('VIP').



The genedrive product achieves all of these criteria and gives us a strong entry
point into the fastest growing market segment of DNA based diagnostics.


We believe that the genedrive platform, when combined with LGC Limited's
HyBeacon technology, should not only enable us to penetrate successfully the VIP
market, but should also allow us to provide other tests for important conditions
in the near patient setting.



The genedrive platform is itself at an advanced stage of development and
substantially all of the research and development expenditure has now been made.
Molecular Sensing, however, is dependent upon partnership and licensing
agreements to bring products to market.



The recent agreement that Osmetech has entered into with IDEXX has demonstrated
our ability to secure partnerships with companies outside the medical industry
and we believe that there are opportunities to market the product for sale in
sectors other than healthcare diagnostics, including forensic and research.



The highly reliable revenue streams from OPTI provide a solid base from which
the business can develop its exciting opportunities for further growth. We will
shortly have three strong technology platforms to meet the needs of the
international diagnostics market - blood-gas analysis, e-nose sensing and
molecular analysis. Osmetech has been transformed from a technology company with
potential into a rapidly developing international diagnostics company operating
in high-growth market sectors.'



This summary should be read in conjunction with the full text of the following
announcement.



Enquiries:


Osmetech Molecular Sensing

James White (Chief Executive Officer) Alison Kibble (Chief Executive Officer)

David Sandilands (Chief Financial Officer)

Tel: 020 7849 6027 Tel: 01225 706 245


Evolution Beeson Gregory Insinger de Beaufort

Rob Collins Stephen Goschalk

Stuart Andrews

Tel: 020 7071 4300 Tel: 020 7377 6161


The Madano Partnership

Matthew Moth

Tel: 08702 40 62 43

LONDON (AFX) - Osmetech PLC said today's all-share offer for Molecular
Sensing PLC is a "dream deal" that will enhance earnings at least as much as its
last deal with IDEXX Laboratories Inc, signed last month.

Though chief executive James White declined to put a figure on how today's
acquisition might boost earnings, he said it will at least be equivalent to the
"significant uplift" in revenues forecast at the time of the IDEXX deal.

Revenues will really start churning through in 2006-2007, following the 2005
launch of Molecular's lead product, White added.

This late-stage product, called the genedrive platform, is a combination of
an instrument platform and chemistry and is used to detect infectious diseases,
mainly vaginal infections.

It would compliment Osmetech's Bacterial Vaginosis test, which can diagnose
sexually transmitted diseases within half an hour and is scheduled for a US
launch in H2 2005.

The BV test, based on the group's electronic nose technology, is being
combined with other tests for diagnosing and differentiating between five of the
most prevalent vaginal infections, including chlamydia and gonorrhoea.

White added that the genedrive platform could also be used in genetic
testing, to test patients for thrombosis, or in the vetinary or forensics
market.

"(The deal) enables us to take a late stage product, put it through our
distribution and manufacturing facility, and get into the fastest growing area
in diagnostics, the molecular diagnostics sector," White told AFX News in a
telephone interview.

Following the acquisition, the company has three main revenue streams: the
gas-analysing OPTI business, the IDEXX deal -- a 10-year agreement to provide
OPTI analysers to the world's largest animal health diagnostics company -- and
this latest, for the vaginal infection or genetic testing.

The Molecular Sensing acquisition strengthens the group's product offering
in the vaginal infection area, and gives it an entree into the genetic testing
market.

"We've got three or four horses out there, they're all going to have a
positive impact, it is a timing issue now," White told AFX.

The market for molecular diagnostics is growing at over 20 pct a year and
the overall diagnostics market is currently worth 22 bln usd.

does any one have any idea why we are having suck GOOD news yet the share price has dropped around 10% in 3 weeks.

it seems that people have not cotton on to the potenial of this company as the price is still falling, with so many new products on there way and with the molecular sensing deal all should be rosy for this one, i will be topping up at this level as potenial med term is excellent, anyone else agree that there should only be blue sky from here on in. cheers windy

Have this one in my Med-Long term folder Windy and can't say I am at all bothered about the current SP. Give it time and reap the rewards.

Regards

PTH